{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:48:34Z","timestamp":1779338914977,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Esophageal cancer has a poor survival outcome with 5-year OS at 16.7% despite treatment. Some inflammation-based prognostic indicators like the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been previously studied as potential biomarker for predicting outcome in esophageal cancer. Recently, platelet-to-albumin ratio (PAR) has been reported as a promising prognostic factor in gastrointestinal malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective analysis of prospectively treated patients of carcinoma esophagus to evaluate the prognostic significance of inflammation-based prognostic indicators\u2014neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and a composite inflammation-nutrition index: platelet-to-albumin ratio (PAR) in esophageal cancer. Based on previous studies, the optimal cut-off value of PAR was kept at 5.7\u2009\u00d7\u200910^9, and 2.62 for NLR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 71 patients of locally advanced esophageal cancer treated between 2019 and 2022, with either neoadjuvant or definitive chemoradiotherapy, were included. Median follow-up time was 19\u00a0months [range: 7\u201344\u00a0months]. Median OS and PFS in our study cohort were 11.3\u00a0months [range: 7\u201323\u00a0months] and 7.8\u00a0months [range: 3\u201317\u00a0months], respectively. In univariate analysis, lower PAR was found to be significantly correlated with shorter survival time (HR\u2009=\u20092.41; 1.3\u20134.76; <jats:italic>p<\/jats:italic>\u2009=\u20090.047). There was no association found between the OS and the NLR [HR\u2009=\u20091.09; 0.95\u20131.26; <jats:italic>p<\/jats:italic>\u2009=\u20090.222]. Univariate and multivariate linear and logistic regressions found no association between V15, V10, V5, or V2 of spleen and nadir lymphocyte count or between Dmax or Dmean and nadir lymphocyte counts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Present analysis found a trend toward an inverse association between PAR and OS. PAR, in the not-so-distant future, may evolve as a novel, convenient, and inexpensive prognostic indicator in esophageal cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-024-00208-4","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T01:15:17Z","timestamp":1707095717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Platelet-to-albumin ratio and radiation-induced lymphopenia\u2014prognostic biomarker for carcinoma esophagus"],"prefix":"10.1186","volume":"36","author":[{"given":"Adrija","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhilash","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram Pukar","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaswin","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyuti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritee A.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayanand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-5211","authenticated-orcid":false,"given":"Supriya","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"issue":"3","key":"208_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"208_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"208_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, Van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol"},{"issue":"24","key":"208_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593\u20138.","journal-title":"N Engl J Med"},{"key":"208_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)60643-6.","journal-title":"Lancet"},{"issue":"5","key":"208_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1759-7714.13311","volume":"11","author":"H He","year":"2020","unstructured":"He H, Chen N, Hou Y, Wang Z, Zhang Y, Zhang G, Fu J. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thoracic cancer. 2020;11(5):1121\u20138.","journal-title":"Thoracic cancer."},{"issue":"3","key":"208_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/1759-7714.12178","volume":"6","author":"G Wu","year":"2015","unstructured":"Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 2015;6(3):275\u201387.","journal-title":"Thorac Cancer"},{"issue":"7","key":"208_CR8","doi-asserted-by":"publisher","first-page":"e0236445","DOI":"10.1371\/journal.pone.0236445","volume":"15","author":"MR Kim","year":"2020","unstructured":"Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ. Inflammatory markers for predicting overall survival in gastric cancer patients: a systematic review and meta-analysis. PLoS ONE. 2020;15(7):e0236445.","journal-title":"PLoS ONE"},{"issue":"7","key":"208_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4251\/wjgo.v9.i7.300","volume":"9","author":"\u00d6 Akg\u00fcl","year":"2017","unstructured":"Akg\u00fcl \u00d6, \u00c7etinkaya E, Yalaza M, \u00d6zden S, Tez M. Prognostic efficacy of inflammation-based markers in patients with curative colorectal cancer resection. World J Gastrointest Oncol. 2017;9(7):300\u20137.","journal-title":"World J Gastrointest Oncol"},{"key":"208_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12935-019-0785-2","volume":"19","author":"H Peng","year":"2019","unstructured":"Peng H, Luo X. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis. Cancer Cell Int. 2019;19:70.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"208_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1245\/s10434-015-4814-7","volume":"23","author":"K Sakurai","year":"2016","unstructured":"Sakurai K, Ohira M, Tamura T, Toyokawa T, Amano R, Kubo N, et al. Predictive potential of preoperative nutritional status in long-term outcome projections for patients with gastric cancer. Ann Surg Oncol. 2016;23(2):525\u201333.","journal-title":"Ann Surg Oncol"},{"key":"208_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-016-2696-0","volume":"16","author":"T Toyokawa","year":"2016","unstructured":"Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, et al. The pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer. 2016;16:722.","journal-title":"BMC Cancer"},{"issue":"12","key":"208_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/1759-7714.12885","volume":"9","author":"GW Xu","year":"2018","unstructured":"Xu GW, Wu HR, Xiong R, Li CW, Liu CQ, Xu MQ, Xie MR. Value of the preoperative neutrophil-to-lymphocyte ratio as a prognostic factor for long-term survival in postoperative esophageal squamous cell carcinoma patients. Thoracic Cancer. 2018;9(12):1707\u201315.","journal-title":"Thoracic Cancer"},{"key":"208_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/TCRM.S320145","volume":"17","author":"V Haksoyler","year":"2021","unstructured":"Haksoyler V, Topkan E. High pretreatment platelet-toalbumin ratio predicts poor survival results in locally advanced nasopharyngeal cancers treated with chemoradiotherapy. Ther Clin Risk Manag. 2021;17:691\u2013700.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"208_CR15","first-page":"811","volume":"35","author":"C Huang","year":"2021","unstructured":"Huang C, Xia YQ, Xiao L, Huang J, Zhu ZM. Combining the platelet-to-albumin ratio with serum and pathologic variables to establish a risk assessment model for lymph node metastasis of gastric cancer. J Biol Regul Homeost Agents. 2021;35(2):811\u20137.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"1","key":"208_CR16","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1038\/s41598-022-07546-0","volume":"12","author":"Z Huang","year":"2022","unstructured":"Huang Z, Zheng Q, Yu Y, Zheng H, Wu Y, Wang Z, et al. Prognostic significance of platelet-to albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy. Sci Rep. 2022;12(1):3535.","journal-title":"Sci Rep"},{"key":"208_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.21873\/invivo.11409","volume":"32","author":"T Saito","year":"2018","unstructured":"Saito T, Toya R, Yoshida N, Shono T, Matsuyama T, Ninomura S, et al. Spleen dose-volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer. In Vivo. 2018;32:1519\u201325.","journal-title":"In Vivo"},{"key":"208_CR18","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.prro.2019.07.010","volume":"10","author":"PSN Van Rossum","year":"2019","unstructured":"Van Rossum PSN, Deng W, Routman DM, Liu AY, Xu C, Shiraishi Y, et al. Prediction of severe lymphopenia during chemoradiation therapy for esophageal cancer: development and validation of a pretreatment nomogram. Pract Radiat Oncol. 2019;10:e16-26.","journal-title":"Pract Radiat Oncol"},{"key":"208_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","volume":"99","author":"R Davuluri","year":"2017","unstructured":"Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:128\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"208_CR20","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1038\/s41598-022-07546-0","volume":"12","author":"Z Huang","year":"2022","unstructured":"Huang Z, Zheng Q, Yu Y, Zheng H, Wu Y, Wang Z, et al. Prognostic significance of platelet-to-albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy. Sci Rep. 2022;12(1):3535.","journal-title":"Sci Rep"},{"issue":"7","key":"208_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073\u201381.","journal-title":"Carcinogenesis"},{"issue":"09","key":"208_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1160\/TH14-12-1067","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(09):449\u201358.","journal-title":"Thromb Haemost"},{"issue":"2","key":"208_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000444807","volume":"43","author":"JB Kral","year":"2016","unstructured":"Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. Transfusion Medicine and Hemotherapy. 2016;43(2):78\u201388.","journal-title":"Transfusion Medicine and Hemotherapy"},{"issue":"1","key":"208_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","volume":"105","author":"JS Palumbo","year":"2005","unstructured":"Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell\u2013mediated elimination of tumor cells. Blood. 2005;105(1):178\u201385.","journal-title":"Blood"},{"issue":"5","key":"208_CR25","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NE, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187\u201396.","journal-title":"Clin Nutr"},{"issue":"2","key":"208_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90\u20139.","journal-title":"Nat Rev Clin Oncol"},{"key":"208_CR27","doi-asserted-by":"publisher","first-page":"ii27","DOI":"10.1093\/annonc\/mdy093","volume":"29","author":"J Arends","year":"2018","unstructured":"Arends J. Struggling with nutrition in patients with advanced cancer: nutrition and nourishment\u2014focusing on metabolism and supportive care. Ann Oncol. 2018;29:ii27-34.","journal-title":"Ann Oncol."},{"issue":"6","key":"208_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/jso.23711","volume":"110","author":"J Lindenmann","year":"2014","unstructured":"Lindenmann J, Fink-Neuboeck N, Koesslbacher M, Pichler M, Stojakovic T, Roller RE, et al. The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. J Surg Oncol. 2014;110(6):645\u201350.","journal-title":"J Surg Oncol"},{"issue":"1","key":"208_CR29","doi-asserted-by":"publisher","first-page":"doy057","DOI":"10.1093\/dote\/doy057","volume":"32","author":"SY Sun","year":"2019","unstructured":"Sun SY, Chen PP, Meng LX, Li L, Mo ZX, Sun CH, et al. High preoperative plasma fibrinogen and serum albumin score is associated with poor survival in operable esophageal squamous cell carcinoma. Dis Esophagus. 2019;32(1):doy057.","journal-title":"Dis Esophagus."},{"issue":"4","key":"208_CR30","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.21873\/invivo.12909","volume":"36","author":"T Aoyama","year":"2022","unstructured":"Aoyama T, Ju M, Komori K, Tamagawa H, Tamagawa A, Morita J, et al. Clinical impact of platelet-to-albumin ratio on esophageal cancer patients who receive curative treatment. In Vivo. 2022;36(4):1896\u2013902.","journal-title":"In Vivo"},{"key":"208_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-12-7","volume":"12","author":"J Wang","year":"2014","unstructured":"Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12:1.","journal-title":"J Transl Med"},{"issue":"12","key":"208_CR32","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/1759-7714.12885","volume":"9","author":"GW Xu","year":"2018","unstructured":"Xu GW, Wu HR, Xiong R, Li CW, Liu CQ, Xu MQ, et al. Value of the preoperative neutrophil-to-lymphocyte ratio as a prognostic factor for long-term survival in postoperative esophageal squamous cell carcinoma patients. Thoracic Cancer. 2018;9(12):1707\u201315.","journal-title":"Thoracic Cancer"},{"issue":"5","key":"208_CR33","first-page":"435","volume":"8","author":"A Sakin","year":"2021","unstructured":"Sakin A, Alay M, Sahin S, Aydemir O, Aldemir MN, Sakin A, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma. North Clin Istanb. 2021;8(5):435\u201342.","journal-title":"North Clin Istanb"},{"key":"208_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/OTT.S77099","volume":"10","author":"X Yang","year":"2015","unstructured":"Yang X, Huang Y, Feng JF, Liu JS. Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: a meta-analysis. Onco Targets Ther. 2015;10:789\u201394.","journal-title":"Onco Targets Ther"},{"key":"208_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00276-017-1893-0","volume":"40","author":"I Varga","year":"2018","unstructured":"Varga I, Babala J, Kachlik D. Anatomic variations of the spleen: current state of terminology, classification, and embryological background. Surg Radiol Anat. 2018;40:21\u20139.","journal-title":"Surg Radiol Anat"},{"issue":"3","key":"208_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","volume":"38","author":"AT Wild","year":"2015","unstructured":"Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38(3):259.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"208_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1756283X16685557","volume":"10","author":"Q Zhao","year":"2017","unstructured":"Zhao Q, Xu X, Yue J, Zhu K, Feng R, Jiang S, et al. Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma. Ther Adv Gastroenterol. 2017;10(2):231\u201341.","journal-title":"Ther Adv Gastroenterol"},{"issue":"12","key":"208_CR38","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.21037\/tcr-21-1765","volume":"10","author":"M Sakaguchi","year":"2021","unstructured":"Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Okada M. Association between unintentional splenic radiation and lymphopenia and high neutrophil\/lymphocyte ratio after radiotherapy in patients with esophageal cancer. Translational Cancer Research. 2021;10(12):5076.","journal-title":"Translational Cancer Research"},{"issue":"6","key":"208_CR39","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.adro.2021.100761","volume":"6","author":"M Alexandru","year":"2021","unstructured":"Alexandru M, Rodica A, Dragos-Eugen G, Mihai-Teodor G. Assessing the spleen as an organ at risk in radiation therapy and its relationship with radiation-induced lymphopenia: a retrospective study and literature review. Adv Radiat Oncol. 2021;6(6):100761.","journal-title":"Adv Radiat Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-024-00208-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T01:16:54Z","timestamp":1707095814000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-024-00208-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1186\/s43046-024-00208-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval: AIIMS ethics committee - IEC-917\/13.12.2022, RP-10\/2022. Informed written consent to participate in the study was provided by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication was obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}